Description: Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Home Page: www.leaptx.com
47 Thorndike Street
Cambridge,
MA
02141
United States
Phone:
617 714 0360
Officers
| Name | Title |
|---|---|
| Mr. Douglas E. Onsi J.D. | CFO, Gen. Counsel, Treasurer & Sec., Pres, CEO & Director |
| Mr. Augustine J. Lawlor | Chief Operating Officer |
| Dr. Cynthia A. Sirard | Chief Medical Officer |
| Mr. Mark O'Mahony | Chief Manufacturing Officer |
| Ms. Christine M. Granfield | VP and Head of Regulatory Affairs & Quality |
| Dr. Jason S. Baum Ph.D. | VP & Head of Translational Medicine |
| Dr. Walter Newman | Sr. Research Fellow |
Exchange: F
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6619 |
| Price-to-Sales TTM: | 138.4532 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |